Skip to content

Recurrent Salivary Gland Infections in Covid-19

Recurrent Salivary Gland Infections in Covid-19

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05890547
Acronym
RecSalivary
Enrollment
60
Registered
2023-06-06
Start date
2023-06-01
Completion date
2023-12-31
Last updated
2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Salivary Gland Infections in Covid-19

Brief summary

The aim of this study is to find out the role of Covid-19 in salivary gland infection and its recurrence.

Detailed description

This is a prospective clinical study of 60 patients. The study will be performed in the Otolaryngology department, Faculty of Medicine, Benha University during the duration from June 2023 to December 2023. Inclusion criteria: Adult patients aged ≥18 years. Exclusion criteria: * Patients with known autoimmune diseases, * Diabetes Mellitus * History of cancer in the region of the head and neck or previous radio and/or chemotherapy. * History of facial nerve palsy, * Oral and dental diseases including chronic sialadenitis or sialolithiasis. * previous oral surgery. Patients were divided into two equal groups each of 30 patients according to the cause of infection. Group (1) comprises 30 patients with Covid-19 infection representing the study group COVID-19 diagnosis will be based on a positive SARS-CoV-2 nasopharyngeal swab on real-time reverse transcription-polymerase chain reaction (RT-PCR) in the presence of clinical and/or radiological signs and group (2) comprises of 30 patients with non-Covid-19 infection as a control group. All patients will be submitted to full ENT and intraoral clinical examination. We will Compare both groups as regards patients' characteristics, risk factors, etiology, symptoms, and rate of recurrence of sialadenitis.

Interventions

None listed

Sponsors

Benha University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients aged ≥18 years with a history of CIVID-19 infection in the study group and of similar age without a history of COVID-19 infection.

Exclusion criteria

* Patients with known autoimmune diseases, * Diabetes Mellitus * History of cancer in the region of the head and neck or previous radio and/or chemotherapy. * History of facial nerve palsy, * Oral and dental diseases including chronic sialadenitis or sialolithiasis. * previous oral surgery.

Design outcomes

Primary

MeasureTime frameDescription
occurrence or recurrence of sialoadenitis6 monthsCompare both groups as regards patients' characteristics, risk factors, etiology, symptoms, and rate of recurrence of sialadenitis.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026